INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the 2^nd^ leading cause of cancer death in the United States. Chemotherapy is the primary form of treatment once CRC has spread beyond the colon. However, in most cases tumors recur and become refractory to chemotherapy. In part, tumor recurrence and chemoresistance is attributed to stochastic genetic and epigenetic changes, which cause selection of resistant clones that form new tumors. Recently, an additional mechanism of tumor recurrence and chemoresistance has been proposed. This mechanism postulates that a minority of cells in a tumor (referred to as cancer stem cells or cancer initiating cells) are intrinsically more chemo- and radiation resistant \[[@R1],[@R2]\]. In support of this model, recent studies have demonstrated that these cells express high levels of DNA damage response genes, which contribute to chemoresistance \[[@R3]\]. They also have lower reactive oxygen species (ROS) levels as another mechanism conferring resistance to radiation, and in fact have less DNA damage after ionizing radiation \[[@R4]\]. These cells also express high levels of drug efflux transporter genes that also lead to chemoresistance and relapse \[[@R5]\].

Recent CRC focused studies show that colon cancer initiating cells (CCIC) are enriched in xenogenic tumors growing in mice treated with chemotherapy, and that CCIC rapidly regenerate new tumors even with concurrent therapy \[[@R6],[@R7]\]. Additionally, high NOTCH signaling levels cause CRC chemoresistance \[[@R8]\] and our own recent studies show that CCIC have 10--30X higher NOTCH levels than non-CCIC CRC cells as a potential mechanism of chemoresistance and tumor recurrence \[[@R9]\].

As CCIC are thought to both self-renew and give rise to non-CCIC CRC cancer cells that populate tumors, epigenetic control of gene expression has been proposed as a likely mechanism to regulate the CCIC to non-CCIC CRC cancer cell transition. Drugs that modulate epigenetic state are therefore a promising approach for anti-CCIC targeted therapy. The covalent modification of histones (such as methylation or acetylation) is an important mechanism of epigenetic regulation. Transcriptionally active gene promoters generally have hyperacetylated chromatin while transcriptionally silent genes have hypoacetylated chromatin. Histone acetyltransferases (HATs) catalyze the addition of acetyl groups onto histones and act as transcription co-activators. Conversely, Histone deacetylases (HDACs) are transcription co-repressors that remove acetyl groups from histones. There are three distinct classes of HDACs. Class I includes HDACs 1,2,3 and 8, Class II HDACs 4-7 and 9-11, and Class III the SIR2 family. HDACs inhibit the expression of target genes to which they are bound by deacetylating Histone 3 at lysines K9 and K14 in target promoters. HDAC inhibitors directly relieve repression of these targets by preventing Histone 3 K9 and K14 de-acetylation. H3 K9/K14 deacetylation causes subsequent trimethylation of H3 on lysine 4 (H3K4me3) to maintain longer-term gene upregulation.

Normal colon mucosa has high levels of Class I HDACs and CRCs have higher histone acetylation levels than normal colon \[[@R10],[@R11]\]. HDAC inhibitor treated *APC* mutant mice develop fewer intestinal adenomas \[[@R12]\]. Therefore, HDAC inhibition, and Class I HDAC inhibition in particular, is thought to be a promising strategy to improve anti-CRC chemotherapy. MGCD0103 is the first Class I selective HDACi to enter clinical trials. Phase I/II clinical studies show that MGCD0103 is active against lymphomas \[[@R13]-[@R15]\]. Currently, non-class specific HDACi are FDA approved for treatment of lymphomas. Both class specific and pan-HDACi are also actively being evaluated in the treatment of a variety of solid tumors as well.

*WNT* signalling plays a critical role in both CCIC and non-CCIC CRC cell proliferation and the majority of CRC tumors have increased *WNT* signaling \[[@R16],[@R17]\]. Canonical *WNT* signaling is initiated by ligand binding to Frizzled-Lrp5/6 cell surface receptors. This binding triggers a signaling cascade that causes β-catenin nuclear translocation. β-catenin binds to LEF/TCF transcription factors and upregulates genes important in proliferation and anti-apoptosis, such as MYC and CCD1. *APC* is a core component of the cytoplasmic "destruction complex" that degrades β-catenin via the proteasome. *APC* mutations are very common in CRC and cause constitutive *WNT* signaling by nuclear β-catenin.

Dickopf (DKK) family proteins are extracellular *WNT* antagonists that bind to LRP5/6 with co-factors. *DKK-1* is thought to be the most important family member in CRC. *DKK-1* causes LRP 5/6 endocytosis and downregulation, inhibiting downstream canonical *WNT* signaling \[[@R18]\]. In transgenic mice, targeted overexpression of *DKK-1* to the intestine inhibits proliferation of intestinal epithelial cells in villi and crypts \[[@R19]\]. *DKK-1* also inhibits epithelial cell polarization and migration, processes that are important in tumor progression and metastasis \[[@R20]\].

*DKK-1* expression is downregulated in human CRC. In many tumors *DKK-1* is epigenetically silenced. In colon cancer cell lines where *DKK-1* is epigenetically silenced, forced expression of *DKK-1* inhibits proliferation and reduces xenograft tumor growth. Overall, *DKK-1* is thought to act as a growth suppressor for CRC \[[@R21]\]. However, the mechanism of *DKK-1* growth inhibition is poorly characterized.

We previously derived CCIC from primary CRCs \[[@R9]\]. To understand the mechanism of CCIC tumor formation we screened a variety of drugs for CCIC anti-proliferative activity. These included standard conventional cytotoxic chemotherapy drugs such as 5-FU and oxaliplatin, EGF Receptor inhibitors, *IGF1* Receptor inhibitors, nitrosylated NSAIDs, and targeted agents including sunitinib and sorafenib, among others. CCIC were also resistant to almost all the agents screened, with the exception of the Class I HDACi MGCD0103. MGCD0103 effectively inhibits CCIC proliferation and clonogenicity. Furthermore, MGCD0103 is also active against commonly used non-CCIC CRC cell lines. These data were confirmed with the non-class specific HDACi Trichostatin (TSA). Gene expression profiling revealed that a mechanism of HDACi induced CCIC growth arrest and apoptosis is upregulation of the *WNT* antagonist *DKK-1*. Overall, our data show that MGCD0103 is a promising approach to target CCIC as well as non-CCIC CRC cells. This dual activity is important because CCIC are highly chemoresistant. Our data also provide evidence that *DKK-1* can inhibit proliferation and clonogenicity even in CCIC that carry *APC* mutations. This result is consistent with a role for DKK1 to inhibit CCIC growth through mechanisms in addition to its role in canonical *WNT* signaling pathways and provides insight into the mechanisms of CCIC proliferation, tumor formation and chemoresistance.

RESULTS {#s2}
=======

HDAC inhibitors have anti-CCIC and non-CCIC CRC cell anti-proliferative activity {#s2_1}
--------------------------------------------------------------------------------

To test if HDAC inhibitors have anti-tumor capacity in colon cancer we tested if Class I HDAC inhibitor MGCD0103 and TSA affected proliferation in colon cancer cell lines. We found that MGCD0103 had anti-proliferative activity against colon cancer cell lines in MTT assays with an IC50 value of 0.7--1.0μM in commonly used CRC cell lines HCT15, HT-29, SW48 and SW620. For comparison the IC50 value for HMEC cells is 19μM (Table [1](#T1){ref-type="table"}). In addition, cell cycle analysis of HCT15 and HCT116 cells treated with MGCD0103 show G2/S phase cell cycle arrest and a sub-G1 accumulation (data not shown). Thus, Class I HDAC inhibitor MGCD0103 inhibits proliferation of colon cancer cell lines and causes cell cycle arrest and apoptosis.

###### MTT IC~50~ Values (mM) of MGCD0103 in Different Human Cancer and Normal Cell Lines

  CELL LINE   IC 50 (μM)
  ----------- ------------
  HCT15       0.7
  HT-29       0.7
  SW48        0.8
  SW620       1.0
  HMEC        19

To test if MGCD0103 had anti-CRC activity in xenograft models we treated mice injected with commonly used CRC cell lines including SW48, Colo 205 and HCT116. When the tumors reached \~100mm^3^ mice were randomized into groups of 6--8 animals and treated with MGCD0103 i.p. or vehicle. Tumors were measured 2--3 times a week for up to 3 weeks. Treatment of mice with MGCD0103 had anti-tumor activity in all commonly used CRC cell lines tested, as well as other solid tumor cell lines. For colon cancer the growth inhibition was 60% in an aggressive xenograft model such as HCT116 and almost complete growth inhibition in Colo205 (Figure [1](#F1){ref-type="fig"}).

![MCCD0103 inhibits xenograft growth of multiple commonly used CRC cell lines\
NOD/SCID mice were injected in the lateral flank with one million cells of the indicated cell line and mice were treated with 40mg/kg MGCD0103 i.p. daily injections for three weeks. The decrease in xenograft tumor volume is indicated. Inhibition is the mean of two independent experiments for each cell line.](oncotarget-01-596-g001){#F1}

MGCD0103 inhibits CCIC viability {#s2_2}
--------------------------------

After demonstrating that MGCD0103 has anti-tumor activity in non-CCIC CRC cell lines, we next evaluated anti-CCIC activity, comparing MGCD0103 to standard conventional cytotoxic chemotherapy agents such as 5-FU, and oxaliplatin and SN38/CPT-11. CCIC viability was significantly impaired by MGCD0103 (Figure [2A](#F2){ref-type="fig"}). Consistent with previous results, CCIC are highly resistant to 5FU/oxaliplatin \[[@R7]\] (Figure [2B](#F2){ref-type="fig"}). Combining 5FU/oxaliplatin and MGCD0103 further decreased CCIC viability and proliferation in a dose dependent manner (Figure [2B](#F2){ref-type="fig"}). To determine if this effect was specific to CCIC we treated CCIC and normal epithelial cell lines in the same experiment. When treated with MGCD0103, CCIC viability was impaired significantly more than MCF10A cells (Figure [2C](#F2){ref-type="fig"}). These data show that the same concentration of MGCD0103 reduces CCIC viability more effectively than the other cell types tested. Similar results were obtained when cells were treated with a pan-HDAC inhibitor TSA (data not shown).

![MGCD0103 impairs viability of CCIC\
Cells were cultured in stem cell media in suspension and treated with MGCD0103 and/or the combination of 5-FU/Oxaliplatin (FOLFOX). MTT assays were performed to assess cell viability after drug treatment. Error bars are S.E.M.](oncotarget-01-596-g002){#F2}

MGCD0103 inhibits CCIC clonogenicity and causes apoptosis in CCIC {#s2_3}
-----------------------------------------------------------------

Next we evaluated whether MGCD0103 inhibited the ability of CCIC to form tumour foci *in vitro* we used a 3D matrigel assay. In this assay CCIC are plated as single cells form tumor foci with organized glandular crypt like lumens and give rise to cells that express non-CCIC CRC cell tumor markers \[[@R9]\] (Figure [3A](#F3){ref-type="fig"}). Using the 3D matrigel *in vitro* culture as previously described we treated CCIC with MGCD0103 for 72h and then cultured in normal media. We then quantified CCIC tumor formation in 3D culture in vitro. MGCD0103 treated cells formed no tumor foci. Only a few single, isolated CCIC cells were still observed (Figure [3B](#F3){ref-type="fig"}). Morphologically, cells have apoptotic bodies and lose self-renewal (Figure [3B](#F3){ref-type="fig"} and data not shown). In summary, both MTS and 3D tumor formation assays are consistent with inhibition of proliferation as a mechanism of MGCD0103 action. Similar results were seen with TSA treatment (data not shown). Furthermore, cells treated with MGCD0103 and TSA were cultured in 3D cultures for up to 2 months after treatment to evaluate if cells can recover from a pulse of HDACi Even after two months of culture CCIC failed to recover and form tumor foci in 3D culture as compared to control. This suggests that HDAC inhibitors not only inhibit proliferation but can induce long-term (possibly permanent) changes in the CCIC epigenetic state that inhibit tumor formation.

![MGCD0103 inhibits CCIC D culture tumor formation\
**A.** Representative pictures of xenograft tumors (left) and 3D culture glandular crypt-like tumors (right) from CCIC cell lines. **B.** Light microscopy view of 10cm plate of CCIC after MGCD0103 treatment in 3D matrigel culture at low magnification (left), 10X (middle) and 40X (right).](oncotarget-01-596-g003){#F3}

To understand if HDACi treatment causes CCIC cell death we performed FACS and cell cycle analysis. This revealed that CCIC initiate apoptosis, indicated by the presence of a sub-G1 peak is present in CCIC treated with TSA (Figure [4A](#F4){ref-type="fig"}). In summary, HDACi causes CCIC cell cycle arrest, which is followed by cell death.

![HDAC inhibitors induce CCIC apoptosis\
FACS cell cycle analysis plot of CCIC treated with vehicle only (mock), 200nM TSA or 800nM TSA for 24 hours.](oncotarget-01-596-g004){#F4}

HDAC inhibitors induce expression of DKK-1 {#s2_4}
------------------------------------------

The epigenetic state of CCIC is thought to be different from non-CCIC CRC cell lines. To identify the mechanism of HDACi induced growth arrest and apoptosis we performed gene expression profiling of two distinct CCIC lines treated with 0.7 μM MGCD0103, 1 μM TSA or mock control for 6 hours. The short time period after treatment was used in order to focus on direct targets of HDAC inhibition rather than downstream indirect transcriptional effects. We used Cyber T analysis to find differentially expressed genes between both groups *i.e.* control *vs.* MGCD0103 and control *vs.* TSA. The pan-HDAC inhibitor TSA treatment caused differential gene expression (DEG) of 4440 target genes common to both CCIC lines, and the Class I HDAC inhibitor MGCD0103 caused DEG of 2040 genes in the same lines. In many experiments, gene array studies can have a high false-positive rate. To minimize the false positive rate, we focused our analysis on genes regulated up or down that were common to both the pan-HDAC and class I specific HDAC inhibitors and seen in both CCIC lines, which gave a set of 1126 DEG. The significantly regulated genes (PPDE = 0.99) in each group were then overlapped to find a common subset of genes that are differentially expressed in both treatment groups (Figure [5A](#F5){ref-type="fig"}). The gene list was used in NIH DAVID (Database for Annotation, Visualization and Integrated Discovery) (<http://david.abcc.ncifcrf.gov/>) resource. DNA damage response and cell cycle arrest were among the top GO categories that are enriched (Table [2](#T2){ref-type="table"}). Notably, the expression of the WNT antagonist *DKK-1* increased 18-fold in CCIC treated with TSA and 7.7-fold in MGCD0103 treated CCIC. To validate the array data we performed q-PCR analysis for *DKK-1* on cells treated with increasing concentrations of TSA. TSA induces *DKK-1* expression in a dose dependant manner, thus validating the array data (Figure [5B](#F5){ref-type="fig"}). Induction of *DKK-1* by MGC0103 is not as robust as TSA under the time frame (6 hr) in qRT-PCR validation (data not shown). Overall, these analyses were consistent with a mechanistic role for *DKK-1* in HDACi induced CCIC growth arrest and apoptosis.

![Gene expression profiling reveals CCIC targets of MGCD0103 and TSA upregulation\
**A.** Venn diagram of differentially expressed genes (DEG) common for 2 CCIC cell lines treated with TSA or MGCD0103. **B.** Treatment with HDAC inhibitors upregulates expression of DKK-1 and DKK-3. Fold upregulation and p-value from quadruplicate data points for each of 2 CCIC lines from Affymetrix array data is shown. **C.** Q-PCR confirmation of DKK-1 upregulation by increasing concentrations of TSA.](oncotarget-01-596-g005){#F5}

###### Top statistically enriched Gene Ontology biological process categories for differentially expressed genes

  Term                                                                     Count   \%       PValue     Benjamini
  ------------------------------------------------------------------------ ------- -------- ---------- -------------
  GO:0007049 cell cycle                                                    66      11.40%   5.84E-15   3.09E-11
  GO:0022402c ell cycle processes                                          52      8.98%    7.76E-11   2.04E-07
  GO:0006259\~DNA metabolic process                                        54      9.33%    1.19E-09   2.08E-06
  GO:0006334\~nucleosome assembly                                          15      2.59%    4.37E-08   5.74E-05
  GO:0000074\~regulation of progression through cell cycle                 36      6.22%    1.58E-07   1.66E-04
  GO:0006950\~response to stress                                           57      9.84%    1.72E-07   1.51E-04
  GO:0051726\~regulation of cell cycle                                     36      6.22%    1.80E-07   1.35E-04
  GO:0031497\~chromatin assembly                                           15      2.59%    2.53E-07   1.66E-04
  GO:0065004\~protein-DNA complex assembly                                 18      3.11%    3.35E-07   1.96E-04
  GO:0006270\~DNA replication initiation                                   9       1.55%    7.03E-07   3.69E-04
  GO:0006260\~DNA replication                                              22      3.80%    1.43E-06   6.84E-04
  GO:0006333\~chromatin assembly or disassembly                            16      2.76%    3.75E-06   0.001639764
  GO:0006974\~response to DNA damage stimulus                              24      4.15%    7.93E-06   0.00319912
  GO:0022403\~cell cycle phase                                             25      4.32%    1.19E-05   0.004469104
  GO:0000279\~M phase                                                      22      3.80%    1.26E-05   0.004392701
  GO:0006268\~DNA unwinding during replication                             6       1.04%    2.38E-05   0.007792704
  GO:0009719\~response to endogenous stimulus                              26      4.49%    3.25E-05   0.009990679
  GO:0032508\~DNA duplex unwinding                                         6       1.04%    4.71E-05   0.013652474
  GO:0032392\~DNA geometric change                                         6       1.04%    4.71E-05   0.013652474
  GO:0048523\~negative regulation of cellular process                      51      8.81%    6.61E-05   0.017204735
  GO:0048519\~negative regulation of biological process                    52      8.98%    9.79E-05   0.024198433
  GO:0006261\~DNA-dependent DNA replication                                12      2.07%    1.01E-04   0.023756591
  GO:0006325\~establishment and/or maintenance of chromatin architecture   21      3.63%    1.45E-04   0.0326071
  GO:0006281\~DNA repair                                                   19      3.28%    1.48E-04   0.031823146
  GO:0000075\~cell cycle checkpoint                                        9       1.55%    1.53E-04   0.031601678
  GO:0000278\~mitotic cell cycle                                           21      3.63%    1.65E-04   0.032719024
  GO:0006323\~DNA packaging                                                21      3.63%    1.87E-04   0.03579105
  GO:0065003\~macromolecular complex assembly                              30      5.18%    1.95E-04   0.035944691
  GO:0007067\~mitosis                                                      17      2.94%    2.07E-04   0.036736724
  GO:0000087\~M phase of mitotic cell cycle                                17      2.94%    2.28E-04   0.039230324

DKK-1 inhibits CCIC proliferation {#s2_5}
---------------------------------

To test if *DKK-1* induced CCIC growth arrest and apoptosis we first transfected CCIC with an expression vector for *DKK-1* or GFP control. Equal numbers of CCIC were plated in 3D culture system to assay tumor foci formation. Cells transfected with *DKK-1* had fewer and smaller tumor foci vs. GFP control (Figure [6A](#F6){ref-type="fig"},[B](#F6){ref-type="fig"}). Next, we used recombinant *DKK-1* to treat CCIC already plated in 3D assays. Again, *DKK-1* caused fewer and smaller tumor foci vs. control (Figure [6C](#F6){ref-type="fig"}). *DKK-1* inhibition of *WNT* signaling is upstream of *APC* and the beta-catenin destruction complex. As mutations in *APC* are common in CRC we tested if *APC* is mutated in CCIC. Western analysis revealed that the two CCIC lines studied both have *APC* protein truncations and no WT *APC* protein (Figure [6D](#F6){ref-type="fig"}). Next, we stained for β-catenin in xenograft samples from these CCIC lines. Nuclear β-catenin is an indicator of active *WNT* signaling. We found that nuclear beta-catenin is present in xenografts derived from both lines and is consistent with active *WNT* signaling (Figure [6E](#F6){ref-type="fig"}). Similar results were seen with 3Dculture CCIC tumors (data not shown). Overall, our data are consistent with *DKK-1* as a potent inhibitor of CCIC proliferation and tumor formation, but through a mechanism that is independent of canonical *WNT* signaling. DISCUSSION:CRC metastatic recurrence and chemoresistance are major causes of cancer related death in the United States. Recent experiments have implicated a role for CCIC in both of these processes. Identifying novel compounds and drug combinations that target both CCIC and non-CCIC CRC cells is an important approach to improve CRC patient outcomes.

![DKK1 inhibits CCIC tumor formation through non-canonical WNT signaling pathways\
Light microscopy of CCIC 3D culture clonogenicity in cells transfected with DKK-1 expression vector (**A**) or addition of recombinant DKK-1 (**C**). **B.** Reduction in CCIC colony number with DKK-1 transfection. Error bars are S.E.M. **D.** Western blot showing loss of wild-type APC in CCIC-1 and CCIC-2 lines. Hela WT APC is shown as a positive control. **E.** Immunohistochemistry of CCIC xenograft tumors stained for beta-catenin.](oncotarget-01-596-g006){#F6}

To identify potential anti-CCIC therapeutics we screened through a number of FDA approved and investigational drugs and found the class I HDACi MGCD0103 to be the most effective of the agents tested. We also found MGCD0103 to effectively inhibit the growth of non-CCIC CRC cells. Since Class I HDACs 1-3 are over expressed in CRC \[[@R22]\] this latter finding is not completely unexpected. However, because CCIC are a minority of cells in tumors, the ability of Class I HDACi to inhibit these cells as well as non-CCIC bulk CRC cells is potentially important. Drugs inhibiting both CCIC and non-CCIC CRC cell tumor formation such as MGCD0103 are anticipated to be particularly promising candidates to take forward in CRC developmental therapeutic clinical trials.

MGCD0103 and TSA induce CCIC cell cycle arrest, and apoptosis. Mechanistically, our study provides insights into the primary targets of HDAC inhibition in CCIC. *DKK-1* is epigenetically silenced in many CRCs but can be dramatically up-regulated by treatment with MGCD0103 or TSA. Consistent with a functional role for *DKK-1*, both transfected and recombinant *DKK-1* significantly reduce CCIC proliferation and clonogenicity in 3D cultures. Overall, our results suggest *DKK-1* may be a useful pharmacogenetic biomarker for MGCD0103 clinical trials for CRC and possibly other solid tumors. Previous studies have shown that promoter hypermethylation causes *DKK-1* silencing in CRC and that this is not an early event but more closely associated with late tumor progression \[[@R21]\]. Because epigenetic state is thought to play an important role in the CCIC to non-CCIC CRC cell transition, it is tempting to speculate that HDACi upregulation of *DKK-1* transcription in CCIC may prevent subsequent promoter methylation in non-CCIC CRC daughter cells. Future immunohistochemistry co-localization studies in CRCs of *DKK-1* and CCIC markers such as ALDH1 or CD44/CD166 (and in parallel co-localization studies with non-CCIC CRC cell markers such as CEA) will be useful to understand the precise role of *DKK-1* expression in both CCIC and non-CCIC CRC cells.

Constitutive activation of canonical *WNT* signaling is a common feature of nearly all CRCs and *DKK-1* has a clearly established role as a canonical *WNT* pathway inhibitor. Mutations in *APC* and less frequently *β-CATENIN* and *AXIN* are known to cause constitutive downstream signaling independent of upstream signals. However recent reports have suggested that upstream signaling from *WNT* inhibitors such as SFRP1, WIF-1 and *DKK-1* inhibit CRC cell growth even in presence of downstream mutations \[[@R21]\]. In contrast to sFRPs which decrease levels of β-CATENIN/LEF1 dependant transcription even in cells carrying *APC* mutations, *DKK-1* has minimal effect on these targets \[[@R21]\]. Because the CCIC lines we studied do not express WT *APC*, our study provides new evidence that *DKK-1* inhibits proliferation through mechanisms that are independent of canonical *WNT* signaling. In mesothelioma cells *DKK-1* activates the JNK pathway to induce apoptosis \[[@R23]\]. Since JNK signaling increases intestinal tumorgenesis in mouse models \[[@R24]\], future additional studies will be helpful to understand the role of JNK and other anti-proliferative mechanisms of *DKK-1* in CCIC and non-CCIC CRC cells that are independent of canonical *WNT* signaling.

MATERIALS AND METHODS {#s3}
=====================

MGCD0103 and TSA treatment of CCIC {#s3_1}
----------------------------------

CCIC were plated in 3D culture (DAY 0) and treated with 0.7μM MGCD0103 (DAY 1) or 200nM TSA and treated for 48h. Controls were treated with DMSO or ethanol respectively. The cells were then cultured without drug for another 14 days or upto 2 months to assay number of colonies formed.

CCIC transfection and DKK-1 treatment {#s3_2}
-------------------------------------

CCIC were transfected with *DKK-1* expression vector (a kind gift from Dr. Marian Waterman) or GFP expression vector using Lipofectamine 2000 overnight. The cells were then trypsinzed counted and equal number of live cells were plated in each well for 3D assays. Recombinant *DKK-1* was purchased from R&D systems. CCIC were plated in 3D wells and treated with rec*DKK-1* at 10ng. CCIC were cultured for 14 days to assay affect on proliferation and colony formation.

Protein Isolation and Western Blotting {#s3_3}
--------------------------------------

CCIC spheres were treated with TSA and cells were collected at different time points. The cell pellets were lysed in ice cold NP40 lysis buffer (50mM Tris-HCl, pH7.5, 150mM NaCl, 1mM EDTA and 1% NP-40). Protein quantification was carried out using Bio-Rad Bradford protein quantification assay. Proteins were separated by SDS/PAGE and transferred to Immobilon-P PVDF (Millipore). Membranes were blocked with 5% nonfat dry milk and then incubated overnight at 4 °C with specific primary antibodies for Acetyl H3K9 and Acetyl H3K4 (Upstate Biotech) at dilutions recommended by the manufacturer. Detection was carried out by peroxidase based chemiluminesence and Dura West substrate (Pierce).

Gene expression profiling {#s3_4}
-------------------------

Two CCIC lines were treated with MGCD0103 (0.71 μM) or TSA (200 nM) for 6h in quadruplicates and RNA was extracted using Qiagen RNeasy Spin columns. Expression profiling was carried out using total RNA from CCIC lines on Affymetrix GeneChip Human Exon 1.0 ST Array. RNA extraction, labeling, hybridization and scanning were carried out according to recommended protocols. The Cybet-T program was used to determine statistically significant differentially expressed genes compared to mock treated samples. Differentially regulated genes were analyzed by Ingenuity Pathway Analysis.

RNA isolation and quantitative RT-PCR {#s3_5}
-------------------------------------

Total RNA was extracted using Qiagen RNeasy Spin columns and reverse transcribed using ABI High capacity cDNA kit. Taqman Assay on demand was used to quantify gene expression on a ABI PRISM HT7900. Gene expression was normalized using GAPDH or RPLPO.
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